Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    50.0%

    Based on 1 completed trials

    Completion Rate
    50%(1/2)
    Active Trials
    0(0%)
    Results Posted
    100%(1 trials)
    Terminated
    1(25%)

    Phase Distribution

    Phase 3
    1
    25%
    Phase 1
    1
    25%
    Phase 4
    1
    25%

    Phase Distribution

    1

    Early Stage

    0

    Mid Stage

    2

    Late Stage

    Phase Distribution3 total trials
    Phase 1Safety & dosage
    1(33.3%)
    Phase 3Large-scale testing
    1(33.3%)
    Phase 4Post-market surveillance
    1(33.3%)

    Highest Phase Reached

    Phase 4

    Trial Status & Enrollment

    Completion Rate

    50.0%

    1 of 2 finished

    Non-Completion Rate

    50.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Completed(1)
    Terminated(1)
    Other(2)

    Detailed Status

    unknown2
    Completed1
    Terminated1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    0
    Success Rate
    50.0%
    Most Advanced
    Phase 4

    Trials by Phase

    Phase 11 (33.3%)
    Phase 31 (33.3%)
    Phase 41 (33.3%)

    Trials by Status

    completed125%
    terminated125%
    unknown250%

    Recent Activity

    0 active trials
    Showing 4 of 4
    completedphase_3

    Efficacy and Safety of GTR in Comparison to Copaxone®

    NCT01489254
    unknownphase_1

    An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome

    NCT02023424
    unknownphase_4

    Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation

    NCT00677664
    terminated

    An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

    NCT00398528

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT01489254Phase 3

    Efficacy and Safety of GTR in Comparison to Copaxone®

    Completed
    NCT02023424Phase 1

    An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome

    Unknown
    NCT00677664Phase 4

    Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation

    Unknown
    NCT00398528

    An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

    Terminated

    All 4 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    4